dishevelled associated activator of morphogenesis 2Genealiases: NPHS24 · dJ90A20A.1
Q-omics provides the consensus-scored DAAM2 profile across patient tissues and cancer cell-line models. DAAM2 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, DAAM2 is differentially expressed in 15, with the highest sampling consensus in COAD. Additionally, DAAM2 RNA expression shows 21,338 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRP, COAD, and GBM as cancer lineages where DAAM2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DAAM2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DAAM2 survival associations across molecular data types. DAAM2 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DAAM2 RNA expression–survival associations across cancer types. High DAAM2 expression shows unfavorable associations in KIRP and ACC, but favorable associations in LUAD, HNSC, LGG and UCS. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify KIRP as the clearest survival context for DAAM2 RNA expression.
This table summarizes DAAM2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 6. The strongest signals are observed in COAD for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for DAAM2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DAAM2 shows lower tumor expression in COAD, LUAD, KICH, THCA, KIRP and BLCA. The COAD box plot shows higher DAAM2 RNA expression in normal versus tumor tissue (log2 FC = −1.540, t-test p < 0.001).
This table shows molecular features associated with DAAM2 in patient tissues and cancer cell lines. In patient samples, DAAM2 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, DAAM2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and SKIN.
